Times BeatsBusiness and general news releases, as issued

Biotech & Pharma · Week of Nov 9, 2026

Lilly reports Foundayo sleep apnea data: the week in biotech releases

Immunic, Tango, PDS, Compugen, Trevi and Protalix posted Q3 results or early data, with most pointing to readouts in 2027.

· Times Beats newsroom

Eli Lilly and Company dominated the week with two releases on its incretin portfolio. Lilly says Foundayo (orforglipron) met the primary endpoint in the Phase 3 ATTAIN-OSA program in obstructive sleep apnea, and it plans to submit for that use by the end of 2026. Ahead of ObesityWeek 2026, the company previewed data on Zepbound, EloraTZP and retatrutide in sleep apnea, knee osteoarthritis pain and adolescent obesity. Both releases present the obesity drugs as treatments for conditions beyond weight.

Smaller developers spent the week on third-quarter results, and most of their updates centred on cash runway and upcoming readouts. Immunic expects Phase 3 ENSURE data in relapsing multiple sclerosis in December 2026. Tango Therapeutics, Compugen and Trevi Therapeutics pointed to pivotal starts or data in 2027 and 2028. PDS Biotechnology reported a PIPE financing led by Nant Capital, LLC. Protalix presented Phase 1 dose data for its uricase candidate PRX-115 at ACR Convergence 2026.

  1. Eli Lilly and Company

    Lilly's Foundayo (orforglipron) significantly reduced obstructive sleep apnea severity, reinforcing its potential to improve health beyond weight loss

    Lilly says Foundayo (orforglipron) cut the apnea-hypopnea index by 21.1 events per hour (43.8%) at 52 weeks in participants not using PAP therapy and by 18.3 events per hour (27.5%) in those using it, versus 4.3 and 5.5 with placebo. Results were presented at the American Heart Association Scientific Sessions 2026 and published in JAMA, and the company plans an FDA submission for this use by the end of 2026.

  2. Eli Lilly and Company

    Lilly to present new data across Zepbound, Foundayo, EloraTZP and retatrutide at ObesityWeek 2026, moving obesity care beyond the scale

    Lilly will present data on Zepbound, Foundayo, EloraTZP, eloralintide and retatrutide at ObesityWeek 2026, November 14 to 17 in Washington, D.C. Data to be presented include weight loss of up to 23.3% at 48 weeks with EloraTZP in a Phase 2 study and a reduction in the apnea-hypopnea index of up to 60.6% at 80 weeks with retatrutide in TRIUMPH-1.

  3. Immunic, Inc.

    Immunic, Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate Update

    Immunic reported a third-quarter net loss of approximately $42.3 million and cash of $132.0 million, which it expects to fund operations into late 2027. Top-line data from the Phase 3 ENSURE-1 and ENSURE-2 trials of vidofludimus calcium in relapsing MS are due in December 2026, with an NDA planned for mid-2027 if results are positive.

  4. Tango Therapeutics, Inc.

    Tango Therapeutics Reports Third Quarter 2026 Financial Results

    Tango Therapeutics reported a third-quarter net loss of $68.4 million and collaboration revenue of $0, after Gilead collaboration research activities concluded, and held $977.5 million in cash and securities. The company plans to start a pivotal Phase 3 study of vopimetostat plus daraxonrasib in front-line MTAP-deleted pancreatic cancer in the first half of 2027, citing ESMO data showing an 82% objective response rate in later-line patients.

  5. PDS Biotechnology Corp

    PDS Biotech Reports Third Quarter 2026 Financial Results

    PDS Biotechnology reported a third-quarter net loss of $7.6 million and cash of $15.2 million. It completed the initial closing of a PIPE financing of up to $22.3 million led by Nant Capital, LLC, with a further closing tied to submitting a registrational Phase 3 protocol for PDS0301 to the FDA, and added Nant Capital designees to its board.

  6. Compugen Ltd.

    Compugen Reports Third Quarter 2026 Results

    Compugen reported third-quarter revenues of approximately $3.8 million and a net loss of approximately $5.8 million, with cash it expects to fund operations into 2029. The MAIA-ovarian trial of COM701 is fully enrolled with 62 patients and results are due by the end of the first quarter of 2027, while Phase 3 results for AstraZeneca's rilvegostomig are now anticipated in the second half of 2027.

  7. Trevi Therapeutics, Inc.

    Trevi Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates

    Trevi Therapeutics reported a third-quarter net loss of $21.5 million and $299.4 million in cash and securities, which it expects to provide runway into 2030. The company plans a Phase 2 trial of about 120 patients in non-IPF ILD-related chronic cough in the first quarter of 2027, with Phase 3 OCEAN-2 and OCEAN-1 topline results expected in the second half of 2027 and the first half of 2028.

  8. Protalix BioTherapeutics, Inc.

    Higher Single PRX-115 Doses Kept Plasma Uric Acid Levels Below Therapeutic Target for Longer Durations

    Protalix says mean plasma uric acid stayed below the 6.0 mg/dL target for up to 12 weeks after a single 36 mg infusion of PRX-115 in its Phase 1 single ascending dose study. The data are being presented at ACR Convergence 2026 on November 10, and Phase 2 RELEASE top-line results are expected in the second half of 2027.

This roundup is written with AI assistance from the press releases listed above, using only what they state. The releases are the companies' own announcements, not Times Beats reporting.